// App-Quantinova.ai

P396 : Adalimumab induction therapy achieves clinical remission and response in chinese patients with Crohn's Disease

Researchers

Presenter

  • Z.H. Ran

Principal Investigators

  • X. Gao

  • Y. Li

  • R.B. Thakkar

  • J.-Q. Sheng

  • M.A. Kamm

  • S. Travis

  • A.M. Robinson

  • K. Wallace

  • M. Shapiro

Medical Centers

  • St Vincents Hospital, Gastroenterology, Fitzroy, Australia

  • Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, ChinaXijing Hospital of the Fourth Military Medical University, Gastroenterology, Xian, ChinaAbbVie Inc., Global Pharmaceutical Research & Development, North Chicago, United States

  • Translational Gastroenterology Unit, Gastroenterology, Oxford, United Kingdom

  • Sixth Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China

  • The Sixth Affiliated Hospital of Sun Yat-sen University, Department of Gastroenterology, Guangzhou, China

  • Xin Hua Hospital to Shanghai Jiao Tong University School of Medicine, Shanghai, China

  • The Military General Hospital of Beijing, PLA, Gastroenterology, Beijing, China

  • The University of Melbourne, Gastroenterology, Parkville, Australia

Locations

  • United States

  • China

  • United Kingdom

  • Australia

Companies

  • N/A

Study Components

Therapeutic Area

  • Gastroenterology (GU)

Disease

  • Crohn's disease

Biomarkers

  • Faecal calprotectin

  • High sensitivity C-reactive protein

Drug/Treatment

  • Adalimumab

Outcome

  • Unknown

Study Design

  • randomized

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved